Specialists Make Case For Distinguishable Biosimilar Names

A coalition of specialist physicians recently asked FDA to assign distinguishable names to biosimilars, saying National Drug Codes would not be a sufficient way for physicians to to track problems with these products. The physicians said many prescribers believe that shared nonproprietary names indicate the drugs are approved for the same indications, which might not always be the case for biosimilars, and any findings of interchangeabilty could become “moot” if all biosimilars share names with the reference product. Eleven organizations...